The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis | Zendy

Niya Zhou | Zendy; Jie Zhao | Zendy; Xiu Huang | Zendy; Hui Shen | Zendy; Wen Li | Zendy; Zhihao Xu | Zendy; Yang Xia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis

Author(s) -

Niya Zhou,

Jie Zhao,

Xiu Huang,

Hui Shen,

Wen Li,

Zhihao Xu,

Yang Xia

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2020.04.09

Subject(s) - afatinib , medicine , lung cancer , oncology , mutation , mutant , cancer , cancer research , epidermal growth factor receptor , biology , genetics , gefitinib , gene

Targeted therapy has been well-documented to improve the outcomes of non-small cell lung cancer (NSCLC) patients carrying activating driver mutations, such as epidermal growth factor receptor (EGFR), translocations in the receptor tyrosine kinase (ALK), c-Ros proto-oncogene 1 receptor tyrosine kinase (ROS1) (1-3). Erb-b2 receptor tyrosine kinase 2 (ErbB2/HER2) mutations have been found in approximately 2–4% of NSCLC cases and are known as carcinogenic mutations with higher prevalence in women and never-smokers (2,4-6). There are increasing evidence supporting the use of anti-HER2 agents in HER2 mutant Original Article

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research